SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	12.27	7.08
Research & Development	29.18	19.98
Operating Expenses	41.45	27.06
Operating Income	-41.45	-27.06
Interest & Investment Income	3.11	1.32
Other Non Operating Income (Expenses)	-1.53	-3.42
Pretax Income	-39.87	-29.16
Net Income	-39.87	-29.16
Net Income to Common	-39.87	-29.16
Shares Outstanding (Basic)	2	2
Shares Outstanding (Diluted)	2	2
Shares Change (YoY)	23.98%	-
EPS (Basic)	-17.98	-16.31
EPS (Diluted)	-17.98	-16.31
EBITDA	-40.92	-
D&A For EBITDA	0.53	-
EBIT	-41.45	-27.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q